文献速递乳腺癌妇科肿瘤支持与姑息治疗

阴道他莫昔芬:不能使用雌激素的绝经后女性阴道萎缩症状的潜在治疗选择

Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen.
PubMed 文献 · Eur J Cancer · 2026-01-29

这项随机、双盲、安慰剂对照的概念验证试验纳入115例绝经后女性(伴或不伴乳腺癌),随机接受每周一次阴道他莫昔芬20mg或安慰剂。治疗3个月后,他莫昔芬组68.6%报告最困扰的阴道萎缩症状为轻度或不存在,安慰剂组仅9.1%(p<0.001),OR为21.76(95%CI 7.36-64.3)。自报结局改善伴随阴道萎缩评分和阴道pH改善(p<0.001)。

要点

  • 阴道他莫昔芬每周20mg可显著改善绝经后女性最困扰的阴道萎缩症状。
  • 3个月时他莫昔芬组68.6%症状轻微或无,安慰剂组9.1%,OR 21.76。
  • 自报症状改善伴随阴道萎缩评分和阴道pH的客观改善。

核心结论

  • 阴道他莫昔芬使超过三分之二女性最困扰的阴道萎缩症状改善,可能源于低雌激素环境下他莫昔芬在阴道的雌激素激动效应。

研究设计与样本

  • 随机、双盲、安慰剂对照的概念验证试验,纳入115例绝经后女性(伴或不伴乳腺癌),按1:1随机接受每周一次阴道他莫昔芬20mg或安慰剂。

主要发现

  • 治疗3个月后,他莫昔芬组37例(68.6%)报告最困扰的阴道萎缩症状为轻度或不存在,安慰剂组5例(9.1%),p<0.001。
  • 以比值比表示,他莫昔芬组3个月后报告无症状或轻微症状的可能性更高,OR 21.76(95%CI 7.36-64.3)。
  • 自报结局改善伴随阴道萎缩评分和阴道pH改善,p<0.001。

临床怎么用

  • 对于不能使用雌激素的绝经后女性(尤其接受抗雌激素治疗的乳腺癌患者),阴道他莫昔芬可能作为阴道萎缩症状的治疗选择。

局限性

  • 需进一步研究改进阴道给药方式并关注子宫内膜安全性问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a great need for non-estrogenic treatment of vulvovaginal atrophy (VVA) symptoms affecting sexual function and quality of life. Women with breast cancer on anti-estrogenic therapy are particularly vulnerable and in need of help. The primary aim of this proof-of-concept trial was to evaluate the efficacy of vaginal tamoxifen in reducing the most troublesome VVA symptom. METHODS: In this randomized, double blind, placebo-controlled study, 115 postmenopausal women, with or without breast cancer, were randomized to 20 mg vaginal tamoxifen once weekly or placebo (1:1). Follow-up after one and three-months of treatment, included self-reported VVA symptoms on the Endocrine Symptom Subscale of FACT-B, and gynecologic exams for VVA score and measurement of vaginal pH and endometrial thickness. FINDINGS: After three months, 37 (68.6 %) of women on vaginal tamoxifen reported their most troublesome VVA symptom to be mild or not present at all, whereas corresponding number in the placebo group was 5 (9.1 %), p < 0.001. Expressed as odds, women on vaginal tamoxifen were more likely to report no or minor symptoms after three-months, OR 21.76 (95 % CI 7.36 - 64.3). The improvement in self-reported outcomes was accompanied by improvements in VVA scores and vaginal pH, p < 0.001. INTERPRETATION: This study has demonstrated that more than two-thirds of the women on vaginal tamoxifen improved in their most troublesome VVA symptom. This is likely due to a tamoxifen-induced estrogen agonistic effects in vagina in a low-estrogen environment. While findings are promising, further studies on improved vaginal administration and endometrial safety concerns are needed.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nyback S, Poromaa IS, Lindman H, et al. Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. Eur J Cancer. 2026. PMID: 41643515. doi:10.1016/j.ejca.2026.116261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。